Northwell Health Makes History: 1st in the US to Immunize Frontline Workers Against COVID-19

December 14, 2020

Northwell Health, after nearly 10 months of managing an illness that has killed nearly 300,000 and sickened more than 15 million Americans, today took a major step toward the end of the COVID-19 pandemic.

Northwell Health system made history by vaccinating the first person in the United States against COVID-19, when it injected Pfizer Inc.’s medication into Sandra Lindsay, an intensive care nurse at Long Island Jewish Medical Center.

Northwell Health First in the U.S. to administer COVID-19 vaccine

Ms. Lindsay’s participation kick-started a long-anticipated vaccination deployment program throughout the US, as well as the first phase of Northwell’s three-stage rollout to essential frontline hospital personnel. Physicians, nurses and any staff member working in direct contact with COVID-19 patients will also soon receive the first of the two-dose regimen.

“Today is V-Day in our fight against COVID-19,” said Michael Dowling, Northwell president and CEO. “This truly is a historic day for science and humanity, one in which we here in New York and across the United States have been waiting for quite some time.”

After receiving the injection, Ms. Lindsay said: “I feel great. It didn’t feel any different that when receiving the annual influenza vaccine. I would like to thank all the frontline workers, all my colleagues who’ve been doing a yeoman’s job to fight this pandemic all over the world. I feel hopeful today.

“I feel relieved. I hope this marks the beginning to the end of a very painful time in our history. I want to instill public confidence that the vaccine is safe. We’re in a pandemic and so we all need to do our part to put an end to the pandemic and to not give up too soon. There’s light at the end of the tunnel.”

Northwell Health received a limited supply of a few thousands doses — to be spread among eight hospitals — of Pfizer’s vaccine, which will require two injections 21 days apart. The vaccine has demonstrated 95-percent efficacy against infection with minimal side effects, and works on messenger RNA (mRNA) technology, which has been in development for several years. mRNA instructs cells in the body to make different proteins.

To vaccinate team members, Northwell Health has prepared a three-phase prioritization matrix to help deploy the vaccine to its over 74,000 team members. The plan factors in a person’s work/geographic area, department specialty, job function and age.

To prepare, Northwell Health invested in procuring more than 20 -70F freezers, which can store about 250,000 doses each. Northwell also stocked up on extra needles, gloves, swabs to help distribute the vaccine once ready, and the health system has been working hand-in-hand with state and federal officials for a rollout.

“This is a major milestone in our battle against COVID-19 and a remarkable effort by our researchers, scientists and health care providers,” said Mark Jarrett, MD, Northwell’s chief quality officer and deputy chief medical officer. “Our detailed plan will push the seamless vaccination of these brave health care workers. We are very excited to enter the final stage of this pandemic.”

Mr. Dowling added: “COVID-19 took our loved ones, disrupted our lives and forced us to deal with unthinkable circumstances. But hope brings prosperity and we never ended our fight. We never did wave the white flag.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version